• 来稿:陈琳   北京市虹天济神经科学研究院

    J Neurol Sci. 2008 Feb  15;265(1-2):131-5.

  •  

  •  

  • Immunomodulation and neuroprotection  with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for  multiple sclerosis and other neuroimmunological/neurodegenerative  diseases

  •  

  • Karussis D, Kassis I, Kurkalli BG,  Slavin S.

  • Department of Neurology and Laboratory  of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics,  Hadassah-Hebrew University Hospital, Ein-Karem, Jerusalem, IL-91120, Israel.  karus@cc.huji.ac.il

  •  

  • Bone marrow (BM) derived mesenchymal  stem cells (MSCs) (non-hematopoietic, stromal cells) can differentiate under  certain circumstances into cells from various neuronal and glial type lineages;  they also exert immunomodulatory effects. For potential clinical applications,  BM-MSCs offer significant practical advantages over other types of stem cells,  since they can be obtained from the adult BM (the patient himself being the  donor) and can be easily cultured and expanded posing in parallel a very low  risk for development of malignancies. We have shown that BM-MSCs cultured with a  cocktail of growth factors (containing FGF and BDNF) differentiate into  neuronal/glial lineage cells with a predominance of cells expressing astrocytes'  markers. BM-MSCs were effective in suppression of chronic EAE in mice and  induced neuroprotection, preserving most of the axons in the CNS of  successfully-treated animals. Histopathological studies revealed that MSCs could  efficiently migrate into the CNS inflamed tissue (both when administered  intravenously and intraventricularly) and differentiated into cells expressing  neural-glial lineage markers. Our preclinical results indicate that bone marrow  can provide a source of stem cells with a potential for migration into inflamed  CNS tissue and differentiation into cells expressing neuronal and glial cell  markers. Such an approach may provide a feasible and practical way for in situ  immunomodulation, neuroprotection and possibly remyelination/regeneration in  diseases like multiple sclerosis. We therefore developed a explorative protocol  for the evaluation of this therapeutic approach in a small group of patients  with MS and other neurodegenerative  diseases.

  •  

  • PMID:  17610906

 


神经保护因子:对胶质细胞毒性作用有效吗?
6-羟多巴胺单侧帕金森病大鼠模型中染料木黄酮的神经保护作用

Previous:

Next:

骨髓间质干细胞的免疫调节和神经保护:拟议治疗多发性硬化症和其他神经免疫疾病及神经退行性疾病